BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 23383037)

  • 1. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.
    Hendrix CW; Chen BA; Guddera V; Hoesley C; Justman J; Nakabiito C; Salata R; Soto-Torres L; Patterson K; Minnis AM; Gandham S; Gomez K; Richardson BA; Bumpus NN
    PLoS One; 2013; 8(1):e55013. PubMed ID: 23383037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate.
    Anton PA; Cranston RD; Kashuba A; Hendrix CW; Bumpus NN; Richardson-Harman N; Elliott J; Janocko L; Khanukhova E; Dennis R; Cumberland WG; Ju C; Carballo-Diéguez A; Mauck C; McGowan I
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1412-21. PubMed ID: 22943559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
    Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women.
    Minnis AM; Gandham S; Richardson BA; Guddera V; Chen BA; Salata R; Nakabiito C; Hoesley C; Justman J; Soto-Torres L; Patterson K; Gomez K; Hendrix CW
    AIDS Behav; 2013 Feb; 17(2):737-47. PubMed ID: 23065145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
    Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
    PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits.
    Clark MR; Friend DR
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1458-66. PubMed ID: 22394281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose pharmacokinetics of oral tenofovir in plasma, peripheral blood mononuclear cells, colonic tissue, and vaginal tissue.
    Louissaint NA; Cao YJ; Skipper PL; Liberman RG; Tannenbaum SR; Nimmagadda S; Anderson JR; Everts S; Bakshi R; Fuchs EJ; Hendrix CW
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1443-50. PubMed ID: 23600365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.
    Dobard C; Sharma S; Martin A; Pau CP; Holder A; Kuklenyik Z; Lipscomb J; Hanson DL; Smith J; Novembre FJ; García-Lerma JG; Heneine W
    J Virol; 2012 Jan; 86(2):718-25. PubMed ID: 22072766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal deployment and tenofovir delivery by microbicide gels.
    Gao Y; Yuan A; Chuchuen O; Ham A; Yang KH; Katz DF
    Drug Deliv Transl Res; 2015 Jun; 5(3):279-94. PubMed ID: 25874971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets for the prevention of HIV infection.
    Gengiah TN; Baxter C; Mansoor LE; Kharsany AB; Abdool Karim SS
    Expert Opin Investig Drugs; 2012 May; 21(5):695-715. PubMed ID: 22394224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.
    Moss JA; Srinivasan P; Smith TJ; Butkyavichene I; Lopez G; Brooks AA; Martin A; Dinh CT; Smith JM; Baum MM
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5125-35. PubMed ID: 24936594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel.
    Gao Y; Katz DF
    PLoS One; 2013; 8(9):e74404. PubMed ID: 24040241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).
    Robinson JA; Marzinke MA; Fuchs EJ; Bakshi RP; Spiegel HML; Coleman JS; Rohan LC; Hendrix CW
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):175-182. PubMed ID: 29135651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of tenofovir's population pharmacokinetic parameters without reliable dosing histories and application to tracing dosing history using simulation strategies.
    Chaturvedula A; Fossler MJ; Hendrix CW
    J Clin Pharmacol; 2014 Feb; 54(2):150-60. PubMed ID: 24203458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Models for predicting effective HIV chemoprevention in women.
    Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
    Liu AY; Yang Q; Huang Y; Bacchetti P; Anderson PL; Jin C; Goggin K; Stojanovski K; Grant R; Buchbinder SP; Greenblatt RM; Gandhi M
    PLoS One; 2014; 9(1):e83736. PubMed ID: 24421901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perspective on progress and gaps in HIV prevention science.
    Kiser PF; Mesquita PM; Herold BC
    AIDS Res Hum Retroviruses; 2012 Nov; 28(11):1373-8. PubMed ID: 22966871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
    Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
    Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques.
    Nuttall J; Kashuba A; Wang R; White N; Allen P; Roberts J; Romano J
    Antimicrob Agents Chemother; 2012 Jan; 56(1):103-9. PubMed ID: 21986823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and placental transfer of single-dose tenofovir 1% vaginal gel in term pregnancy.
    Beigi R; Noguchi L; Parsons T; Macio I; Kunjara Na Ayudhya RP; Chen J; Hendrix CW; Mâsse B; Valentine M; Piper J; Watts DH
    J Infect Dis; 2011 Nov; 204(10):1527-31. PubMed ID: 21930612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.